Enlivex Therapeutics Ltd.
ENLV
$1.09
$0.0454.31%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -14.33M | -15.01M | -18.93M | -22.29M | -25.99M |
| Total Depreciation and Amortization | 447.00K | 545.00K | 709.00K | 762.00K | 814.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.48M | 2.68M | 4.89M | 4.30M | 4.70M |
| Change in Net Operating Assets | -726.00K | -1.22M | -870.00K | 212.00K | -1.77M |
| Cash from Operations | -13.12M | -13.01M | -14.20M | -17.02M | -22.25M |
| Capital Expenditure | -92.00K | -103.00K | -75.00K | -95.00K | -117.00K |
| Sale of Property, Plant, and Equipment | 2.41M | 2.29M | 2.05M | 276.00K | 357.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 4.82M | 6.87M | 7.86M | 12.20M | 10.24M |
| Cash from Investing | 7.13M | 9.06M | 9.84M | 12.38M | 10.48M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 6.76M | 7.10M | 5.35M | 5.10M | 693.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -110.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -636.00K | -646.00K | -153.00K | -153.00K | -17.00K |
| Cash from Financing | 6.13M | 6.45M | 5.19M | 4.94M | 566.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 139.00K | 2.51M | 828.00K | 304.00K | -11.21M |